Advances in Immunology

1. Auflage 1999
ISBN: 978-0-08-052447-4
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band Volume 73, 558 Seiten, Web PDF

Reihe: Advances in Immunology

Advances in Immunology presents current developments as well as comprehensive reviews in immunology. Articles address the wide range of topics that comprise immunology, including molecular and cellular activation mechanisms, phylogeny and molecular evolution, and clinical modalities. Edited and authored by the foremost scientists in the field, each volume provides up-to-date information and directions for future research.

Autoren/Hrsg.

Inhaltsverzeichnis

1;Cover;1
2;Contents;6
3;Contributors;10
4;Chapter 1. Mechanisms of Exogenous Antigen Presentation by MHC Class I Molecules in Vitro and in Vivo Implications for Generating CD8+ T Cell Responses to Infectious Agents, Tumors, Transplants, and Vaccines;12
4.1;I. Introduction;12
4.2;II. Supporting Information;15
4.3;III. Processing and Presentation of Exogenous Antigens: Reviewing the Recent Literature;37
4.4;IV. Conclusion: Basic Questions;74
4.5;References;75
5;Chapter 2. Signal Transduction Pathways That Regulate the Fate of B Lymphocytes;90
5.1;I. Introduction;90
5.2;II. B Cell Antigen Receptor Complex;100
5.3;III. Coreceptor Regulation of BCR Signaling;117
5.4;IV. Regulation of BCR-Induced Responses by CD40;133
5.5;V. CD95/Fas-Mediated Signaling and BCR-Mediated Resistance to CD95/Fas-Induced Death;143
5.6;VI. General Comments and Concluding Remarks;145
5.7;References;146
6;Chapter 3. Oral Tolerance Mechanisms and Therapeutic Applications;164
6.1;I. Introduction;164
6.2;II. Mechanisms of Oral Tolerance;169
6.3;III. Immune Functions Affected by Oral Tolerance;185
6.4;IV. Factors Affecting Oral Tolerance Induction and Maintenance;189
6.5;V. Modulation of Oral Tolerance;212
6.6;VI. Nasal Tolerance;214
6.7;VII. Other Forms of Antigen-Driven Tolerance;217
6.8;VIII. Treatment of Autoimmune and Inflammatory Diseases in Animals;219
6.9;IX. Treatment of Autoimmune Diseases in Humans;236
6.10;X. Future Directions;243
6.11;References;243
7;Chapter 4. Caspases and Cytokines: Roles in Inflammation and Autoimmunity;276
7.1;I. Introduction;276
7.2;II. The Caspase Family;276
7.3;III. Caspases and Cytokines;278
7.4;IV. Conclusions;298
7.5;References;298
8;Chapter 5. T Cell Dynamics in HIV-1 Infection;312
8.1;I. Introduction;312
8.2;II. Normal T Cell Renewal from Progenitors;314
8.3;III. T Cell Renewal from Progenitors in HIV-1 Infection;316
8.4;IV. Getting Quantitative on CD4+ T Cell Production;320
8.5;V. Measuring Cell Division with the Ki67 mAb;327
8.6;VI. What Is the Cause of CD4+ T Cell Depletion in HIV-1 Infection?;331
8.7;VII. Appendix: Summarizing in Terms of a Mathematical Model;334
8.8;References;335
9;Chapter 6. Bacterial CpG DNA Activates Immune Cells to Signal Infectious Danger;340
9.1;I. Introduction;340
9.2;II. Bacterial DNA and CpG Motifs History of Unraveling Immunobiology;342
9.3;III. Binding and Cellular Uptake of ODNs;344
9.4;IV. Sequence-Independent Effects of the Backbone;344
9.5;V. CpG DNA Sequence-Specific Effects on B Cells;345
9.6;VI. CpG DNA Sequence-Specific Effects on APCs;347
9.7;VII. CpG DNA Effects on T Cells;349
9.8;VIII. CpG[S]ODN Effects on NK Cells;350
9.9;IX. CpG Motifs Affect Plasmid DNA Biology in Gene Vaccination;351
9.10;X. Sequence-Specific Effects of Poly(G) Motifs;352
9.11;XI. Immunosuppressive CpG DNA Motifs;353
9.12;XII. CpG-ODN-Mediated Signaling;353
9.13;XIII. Sensing of Pathogen DNA Evolutionary Vestige of Foreign DNA;357
9.14;XIV. CpG DNA Acts as Adjuvant for Th1 Responses;359
9.15;XV. CpG DNA Mediates Harmful Effects in Vivo;360
9.16;XVI. CpG DNA Acts as Adjuvant for Antitumor Responses;360
9.17;XVII. CpG DNA Reverts Th2-Oriented Pathology;361
9.18;XVIII. CpG DNA Acts as Adjuvant for Mucosal Immunity;362
9.19;XIX. CpG DNA Causes Extramedullary Hematopoiesis;362
9.20;XX. CpG DNA Activates Human Immune Cells;363
9.21;XXI. CpG DNA Mediates Signaling Stimulation versus Costimulation;363
9.22;XXII. CpG DNA Allows MHC Class I-Restricted CTL Responses to Exogeneous Antigens;364
9.23;XXIII. Concluding Remarks;366
9.24;References;367
10;Chapter 7. Neutrophil-Derived Proteins: Selling Cytokines by the Pound;380
10.1;I. Introduction;380
10.2;II. General Features of Cytokine Production by Neutrophils;380
10.3;III. Production of Specific Cytokines by Neutrophils in Vitro;384
10.4;IV. Production of Cytokines by Neutrophils Isolated from Individuals Affected by Different Pathologies;437
10.5;V. Modulation of Cytokine Production in Human Neutrophils;451
10.6;VI. Molecular Regulation of Cytokine Production in Neutrophils;458
10.7;VII. Cytokine Production by Neutrophils in Vivo;464
10.8;VIII. Concluding Remarks;487
10.9;References;490
11;Chapter 8. Murine Models of Thymic Lymphomas: Premalignant Scenarios Amenable to Prophylactic Therapy;522
11.1;I. Introduction;522
11.2;II. Immunobiology of the Thymus in Relation to Lymphomagenesis;524
11.3;III. Thymic Lymphomas of AKR Mice;525
11.4;IV. Prelymphoma Cells in AKR Mice;526
11.5;V. Carcinogen-Induced Lymphomas;527
11.6;VI. Thymic Lymphomas Induced by Fractionated Irradiation;529
11.7;VII. RadLV-Induced Lymphomagenesis;550
11.8;VIII. Preventive Therapy of Prelymphoma Mice;535
11.9;IX. Concluding Remarks;540
11.10;References;541
12;Index;552
13;Contents of Recent Volumes;568